Literature DB >> 2188822

Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension. An overview.

C M Ferrario1.   

Abstract

Current leading theories of the mechanisms of essential hypertension include the participation of the renin-angiotensin-aldosterone system (RAS). Recent advances provide means for a critical reassessment of this system in the physiology and pathology of hypertension. The expression of the proteins of the RAS in organs other than the kidneys suggests that angiotensin II also acts as a modulator of cell function. This paper discusses the role of tissue angiotensin peptides in the regulation of blood pressure and suggests new ideas with regard to the importance of the brain RAS in the development of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2188822     DOI: 10.2165/00003495-199000392-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  39 in total

Review 1.  Structure and function of renin.

Authors:  T Inagami
Journal:  J Hypertens Suppl       Date:  1989-04

2.  Epidemiology of renin.

Authors: 
Journal:  Lancet       Date:  1983-04-02       Impact factor: 79.321

3.  Autocrine-paracrine mechanisms of vascular myocytes in systemic hypertension.

Authors:  V J Dzau; G H Gibbons
Journal:  Am J Cardiol       Date:  1987-12-14       Impact factor: 2.778

4.  The distribution of angiotensin II-immunoreactive cells and fibers in the paraventriculo-hypophysial system of the rat.

Authors:  R W Lind; L W Swanson; T O Bruhn; D Ganten
Journal:  Brain Res       Date:  1985-07-08       Impact factor: 3.252

5.  Interactions between coronary occlusion and the renin-angiotensin system in the dog.

Authors:  G Ertl; R W Alexander; R A Kloner
Journal:  Basic Res Cardiol       Date:  1983 Sep-Oct       Impact factor: 17.165

6.  Angiotensin II binding sites in the conduction system of rat hearts.

Authors:  K Saito; J S Gutkind; J M Saavedra
Journal:  Am J Physiol       Date:  1987-12

7.  Angiotensin-sensitive neurons in the rat paraventricular nucleus: relative potencies of angiotensin II and angiotensin III.

Authors:  J W Harding; D Felix
Journal:  Brain Res       Date:  1987-04-28       Impact factor: 3.252

Review 8.  Angiotensin converting enzyme inhibitors. Present and future.

Authors:  E D Frohlich
Journal:  Hypertension       Date:  1989-05       Impact factor: 10.190

9.  Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors.

Authors:  C I Johnston; F A Mendelsohn; R B Cubela; B Jackson; M Kohzuki; B Fabris
Journal:  J Hypertens Suppl       Date:  1988-12

10.  Modification of arterial baroreflexes by captopril in essential hypertension.

Authors:  G Mancia; G Parati; G Pomidossi; G Grassi; G Bertinieri; N Buccino; A Ferrari; L Gregorini; L Rupoli; A Zanchetti
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

View more
  11 in total

Review 1.  Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.

Authors:  C Csajka; T Buclin; H R Brunner; J Biollaz
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

Review 2.  End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function.

Authors:  Giuliano Tocci; Massimo Volpe
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

3.  Angiotensin II induces membrane trafficking of natively expressed transient receptor potential vanilloid type 4 channels in hypothalamic 4B cells.

Authors:  Ashwini Saxena; Martha Bachelor; Yong H Park; Flavia R Carreno; T Prashant Nedungadi; J Thomas Cunningham
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-30       Impact factor: 3.619

Review 4.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

5.  A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys.

Authors:  A Roccon; D Marchionni; F Donat; D Segondy; C Cazaubon; D Nisato
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

6.  Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats.

Authors:  Chu-Lin Chou; Yu-Hsien Lai; Teng-Yi Lin; Tony J F Lee; Te-Chao Fang
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

7.  Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide.

Authors:  Laura M G Meems; Ingrid A Andersen; Shuchong Pan; Gail Harty; Yang Chen; Ye Zheng; Gerald E Harders; Tomoki Ichiki; Denise M Heublein; Seethalakshmi R Iyer; S Jeson Sangaralingham; Daniel J McCormick; John C Burnett
Journal:  Hypertension       Date:  2019-04       Impact factor: 9.897

8.  Early Training-Induced Reduction of Angiotensinogen in Autonomic Areas-The Main Effect of Exercise on Brain Renin-Angiotensin System in Hypertensive Rats.

Authors:  Laiali Jurdi Chaar; Tatiana Pereira Alves; Alvaro Martins Batista Junior; Lisete Compagno Michelini
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

Review 9.  Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan.

Authors:  Jasmina Varagic; Henry Punzi; Carlos M Ferrario
Journal:  Integr Blood Press Control       Date:  2014-11-26

10.  Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.

Authors:  Gan Mi Wang; Liang Jin Li; Wen Lu Tang; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2020-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.